SHLT VS HARP Stock Comparison
Performance
SHLT10/100
10/100
SHLT returned -38.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
HARP100/100
100/100
HARP returned 4.76% in the last 12 months. Based on SPY's performance of -13.20%, its performance is above average giving it a score of 100 of 100.
Profit
SHLT56/100
56/100
Out of the last 20 quarters, SHLT has had 8 profitable quarters and has increased their profits year over year on 6 of them.
HARP10/100
10/100
Out of the last 20 quarters, HARP has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
SHLT50/100
50/100
SHLT has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.
HARP46/100
46/100
HARP has had a lower than average amount of volatility over the last 12 months giving it a score of 45 of 100.
Sentiment
SHLT
"Sentiment" not found for SHLT
HARP69/100
69/100
HARP had a bullish sentiment score of 68.77% across Twitter and StockTwits over the last 12 months. It had an average of 17.36 posts, 7.05 comments, and 20.50 likes per day.
Technicals
SHLT
"Technicals" not found for SHLT
HARP86/100
86/100
HARP receives a 85 of 100 based on 14 indicators. 12 are bullish, 2 are bearish.
Earnings
SHLT
"Earnings" not found for SHLT
HARP10/100
10/100
HARP has missed earnings 9 times in the last 20 quarters.
All score calculations are broken down here to help you make more informed investing decisions
SHL Telemedicine Ltd American Depositary Shares Summary
Nasdaq / SHLT
Healthcare
Medical - Healthcare Information Services
SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. The company offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; Cardio'B, a portable device to transmit a 12-lead ECG; and Cardio Beeper 12/12, a hand-held ECG transmitter device for personal use that transmits a full ECG reading to the monitoring center. It also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices; TeleWeight, a trans-telephonic weight monitoring device for personal use; TelePress, a remote blood pressure monitoring device for personal use; TeleBreather, a remote electronic handheld device to test the working of lungs; and TelePulse Oximeter, an electronic handheld diagnostic device to measure the saturation level of oxygen in blood, as well as pulse rate. The company offers its telemedicine services and devices to subscribers using telephonic and internet communication technology. It serves patients, health insurance companies, hospitals, clinics, physicians, and other health care providers. The company has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and collaboration agreement with the Hebrew University of Jerusalem and the Hadassah Medical Center to develop an artificial intelligence tool for predicting future life-threatening cardiac events based on 12 Lead ECG monitoring. SHL Telemedicine Ltd. was founded in 1987 and is headquartered in Tel Aviv, Israel.
Harpoon Therapeutics, Inc. Common Stock Summary
Nasdaq / HARP
Healthcare
Biotechnology
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare SHLT to other companies in the same or a similar industry.